Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06613100 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT06613100 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06613100, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.
Conditions Studied
Interventions
- DRUG Xaluritamig
- DRUG GnRH Antagonist
Study Locations (8)
Other
- Universitaetsklinikum Essen - Essen
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
California
- University of California San Francisco - San Francisco
Missouri
- Washington University - St Louis
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Thomas Jefferson University - Philadelphia
Washington
- Fred Hutchinson Cancer Center - Seattle
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2030-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06613100
The ClinicalTrials.gov registry entry for NCT06613100 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Xaluritamig is the first listed.
NCT06613100 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06613100 about?
NCT06613100 is a clinical study titled "Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer". The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility an...
What is the current status of trial NCT06613100?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-11-25. Estimated completion is 2030-01-23.
What conditions does trial NCT06613100 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06613100?
The interventions under investigation include: Xaluritamig (DRUG), GnRH Antagonist (DRUG).
Who is sponsoring clinical trial NCT06613100?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06613100 being conducted?
This trial has 8 study locations across California, Missouri, Ohio, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.